Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Adenine
/ administration & dosage
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Atrial Fibrillation
/ chemically induced
Bendamustine Hydrochloride
/ administration & dosage
Female
Follow-Up Studies
Humans
Hypertension
/ chemically induced
Infections
/ chemically induced
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Male
Piperidines
/ administration & dosage
Prognosis
Rituximab
/ administration & dosage
Survival Rate
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
26
01
2021
accepted:
30
06
2021
revised:
25
06
2021
pubmed:
19
7
2021
medline:
1
1
2022
entrez:
18
7
2021
Statut:
ppublish
Résumé
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) comparisons. We introduce the AE burden score (AE
Identifiants
pubmed: 34274940
doi: 10.1038/s41375-021-01342-x
pii: 10.1038/s41375-021-01342-x
pmc: PMC8744070
mid: NIHMS1720569
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Adenine
JAC85A2161
Banques de données
ClinicalTrials.gov
['NCT01886872']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2854-2861Subventions
Organisme : NCI NIH HHS
ID : UG1 CA233331
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA114725
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192928
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177292
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233253
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183444
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA198183
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180863
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233327
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:vi50–4.
doi: 10.1093/annonc/mdr377
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood.2009;114:3382–91.
doi: 10.1182/blood-2009-02-206185
Eichhorst B, Fink AM, Bahlo J, Busch R, Math D, Kovacs G. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42.
doi: 10.1016/S1470-2045(16)30051-1
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P. et al. RESONATE-2 investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl J Med. 2015;373:2425–37.
doi: 10.1056/NEJMoa1509388
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N. Engl J Med. 2018;379:2517–28.
doi: 10.1056/NEJMoa1812836
Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections. Blood Rev. 2018;32:387–99.
doi: 10.1016/j.blre.2018.03.004
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL. et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103:1502–10.
doi: 10.3324/haematol.2018.192328
National Cancer Institute: CTEP. Common terminology criteria for adverse events (CTCAE) Version 4.0. Bethesda, MD: National Institutes of Health; 2009.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
doi: 10.1080/01621459.1999.10474144
Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The imperative for a new approach to toxicity analysis in oncology clinical trials. J Natl Cancer Inst. 2015;107:djv216. https://doi.org/10.1093/jnci/djv216 .
Carbini M, Suárez-Fariñas M, Maki RG. A method to summarize toxicity in cancer randomized cinical trials. Clin Cancer Res. 2018;24:4968–75.
doi: 10.1158/1078-0432.CCR-17-3314
Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A. et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8:613–24.
doi: 10.1016/S1470-2045(07)70144-4
Lee SM, Hershman DL, Martin P, Leonard JP, Cheung YK. Toxicity burden score: a novel approach to summarize multiple toxic effects. Ann Oncol. 2012;23:537–41.
doi: 10.1093/annonc/mdr146
Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A. et al. Adverse event burden score – a versatile summary measure for cancer clinical trials. Cancers. 2020;12:3251.
doi: 10.3390/cancers12113251
Schuurhuizen CS, Verheul HM, Braamse AM, Buffart LM, Bloemendal HJ, Dekker J. et al. The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy. Cancer Manag Res. 2018;10:3015–21.
doi: 10.2147/CMAR.S166468
Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L. et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32:83–9.
doi: 10.1200/JCO.2013.52.2219
Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, Ballman KV. et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central cancer treatment group and american college of surgeons oncology group investigation. J Clin Oncol. 2010;28:3002–7.
doi: 10.1200/JCO.2009.27.4282
George GC, Barata PC, Campbell A, Chen A, Cortes JA, Hyman DM, et al. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019;76:33–40.
doi: 10.1016/j.ctrv.2019.04.004
Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985–8.
doi: 10.1182/blood-2017-12-823393
Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z. et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;33:2527–30.
doi: 10.1038/s41375-019-0481-1
Shanafelt TD, Wang V, Kay NE, Hanson CA, O’Brien SM, Barrientos JC. et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial. Blood. 2019;134:33.
doi: 10.1182/blood-2019-126824